News Author: Lucas Franki Publish date: January 8, 2018
The VA has developed a new checklist which will be tested in hopes of reducing MRSA surgical site infections.
News Author: Lucas Franki Publish date: January 5, 2018
Denosumab, which is not cleared through the kidneys, offers multiple myeloma patients bone protection with a convenient subcutaneous administration...
News Author: Lucas Franki Publish date: January 3, 2018
Less disability, greater functional independence, and less neurologic deterioration was observed for thrombectomy plus standard care.
News Author: Lucas Franki Publish date: January 3, 2018
Increase in ASD prevalence rates are not statistically significant, epidemiologists report.
News Author: Lucas Franki Publish date: December 28, 2017
After a median follow-up period of 45.4 months, an invasive disease event occurred in 7.1% of all patients who received pertuzumab (Perjeta) and in...
News Author: Lucas Franki Publish date: December 27, 2017
Nivolumab was approved for the adjuvant treatment of melanoma patients with involvement of lymph nodes or in patients with metastatic disease who h...
News Author: Lucas Franki Publish date: December 15, 2017
Topical solution should be used only in the office of a health care provider, not in the home.
News Author: Lucas Franki Publish date: December 14, 2017
It is the third biosimilar of Remicade to be approved by the FDA.
News Author: Lucas Franki Publish date: December 12, 2017
An interventional trial to examine robotic platform efficacy is currently recruiting patients who require inguinal hernia repair surgery.
News Author: Lucas Franki Publish date: December 6, 2017
Immune recruitment into the liver in NAFLD may explain the discrepancy.
News Author: Lucas Franki Publish date: December 1, 2017
Intravenous saline products and amino acids for injection are both in short supply.
News Author: Lucas Franki Publish date: November 17, 2017
The agency reported preliminary findings from a postmarketing safety study started after febuxostat’s approval in 2009.
News Author: Lucas Franki Publish date: November 17, 2017
Approval is based on a 28% lower risk of disease progression or death after 2 years for patients on the obinutuzumab-based regimen.
News Author: Lucas Franki Publish date: November 15, 2017
The anti–tumor necrosis factor alpha agent appears to be safe and effective for both diseases, especially when the rheumatoid arthritis flared.
News Author: Lucas Franki Publish date: November 13, 2017
The drug has previously been approved for use in adults.
